Royalty Pharma plc
RPRX
$60.85
-$1.07-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.39% | -24.17% | -9.90% | -32.94% | 52.06% |
| Total Depreciation and Amortization | 258.09% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 28.79% | 51.39% | 46.39% | 38.25% | 27.43% |
| Total Other Non-Cash Items | 21.22% | -10.71% | -44.30% | -16.49% | -93.35% |
| Change in Net Operating Assets | 12.39% | 10.40% | 9.91% | 6.62% | 8.36% |
| Cash from Operations | 23.70% | -3.28% | -10.08% | -14.07% | -9.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 99.70% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -75.50% | -20.79% | 42.51% | 62.25% | 41.08% |
| Cash from Investing | -66.87% | -24.35% | 39.73% | 59.91% | 38.03% |
| Total Debt Issued | -- | 119.51% | 119.51% | 77.32% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -550.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 72.02% | 39.40% | -434.46% | -478.76% | -359.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.04% | -2.48% | -0.47% | -1.46% | -2.30% |
| Other Financing Activities | -1.99% | 1.38% | -6.12% | -3.40% | -1.28% |
| Cash from Financing | 86.09% | -40.52% | -428.39% | -395.53% | -214.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.90% | -304.86% | -168.65% | -181.65% | -177.34% |